<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04772131</url>
  </required_header>
  <id_info>
    <org_study_id>PS200005</org_study_id>
    <nct_id>NCT04772131</nct_id>
  </id_info>
  <brief_title>Desara ® One Single Incision Sling 522 Study</brief_title>
  <official_title>Prospective, Post-market Study of the Desara® One Single Incision Sling vs. Desara® Blue Sling Implanted Via the Transobturator Route for the Treatment of Women With Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Caldera Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Caldera Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A post-market study to compare the safety and effectiveness of the Desara® One Single&#xD;
      Incision Sling (SIS), when compared to that of an FDA cleared transobturator sling over a&#xD;
      period of 36 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, non-randomized, parallel cohort, multi-center study of Desara®&#xD;
      One single incision sling (SIS) compared to Desara® Blue sling systems implanted via the&#xD;
      transobturator-route (TOR) for the treatment of women with stress urinary incontinence (SUI).&#xD;
      The study will compare results from SIS patients (N=150) and TOR patients (N=150) at up to 40&#xD;
      sites for a total period of 36 months, with follow-up visits at 2 and 6 weeks, 6, 12, 18, 24&#xD;
      and 36 months. This study will enroll adult females who are clinically indicated for a&#xD;
      mid-urethral implant for the treatment of female stress urinary incontinence (SUI) resulting&#xD;
      from urethral hypermobility and/or intrinsic sphincter deficiency (ISD).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 2026</completion_date>
  <primary_completion_date type="Anticipated">November 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Adult female subjects, who in the opinion of their physician require surgical treatment or who have already been diagnosed with stress urinary incontinence, will be eligible for study participation. Subjects who provide informed consent will undergo screening and baseline assessments. Subjects who successfully meet the study's inclusion and exclusion criteria will be eligible to undergo a Desara SIS or Desara Blue implant procedure, with subsequent follow-up assessments. The choice of implant, Desara One or Desara Blue, will be determined by the investigator based upon patient pathology and surgical preference.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate of negative standing cough stress test (CST)</measure>
    <time_frame>36 months</time_frame>
    <description>Negative standing cough stress test (CST) with bladder pre-fill to subjective fullness with 200-300 mL, or with bladder fullness confirmed via ultrasound, evaluated at the 36-month post-implant follow-up visit. The success rate is defined as the proportion of subjects with a negative CST at the 36-month post-implant follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device and Procedure-related serious adverse events</measure>
    <time_frame>36 months</time_frame>
    <description>Device- and/or procedure-related adverse event rates at the post-implant follow-up visits&#xD;
Revision/re-surgery rates at post-implant follow-up visits&#xD;
Device and/or procedure-related serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite outcome success rates</measure>
    <time_frame>6 weeks, 6, 12, 18, 24, 36 months</time_frame>
    <description>Defined by the primary effectiveness endpoint and subjective measure of Improvement in the Patient Global Impression of Improvement (PGI-I) index for incontinence post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual Function Assessment</measure>
    <time_frame>6 weeks, 6, 12, 18, 24, 36 months</time_frame>
    <description>Use of PISQ-12: Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire to assess subject changes in sexual function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Incontinence</measure>
    <time_frame>6 weeks, 6, 12, 18, 24, 36 months</time_frame>
    <description>Use of PGI-I: Patients Global Impression of Improvement index for incontinence to assess subject improvement post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Urinary Symptoms</measure>
    <time_frame>6 weeks, 6, 12, 18, 24, 36 months</time_frame>
    <description>Use of IIQ-7: Incontinence Impact Questionnaire, Short Form and ICIQ-UI: International Consultation on Incontinence Questionnaire-Urinary Incontinence to assess improvement in urinary symptoms post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Urge and Stress Incontinence</measure>
    <time_frame>6 weeks, 6, 12, 18, 24, 36 months</time_frame>
    <description>Use of UDI-6 SF: Urinary Distress Inventory, Short Form to assess subject improvement in urge and stress incontinence post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject pain assessment</measure>
    <time_frame>6 weeks, 6, 12, 18, 24, 36 months</time_frame>
    <description>Use of Numeric Rating 10-point scale (NRS) to assess post-operative pain. Pain scale is 0= no pain to 10 = worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to void post-implant</measure>
    <time_frame>6 weeks, 6, 12, 18, 24, 36 months</time_frame>
    <description>Perform a standard post void residual test to confirm that the subject's residual urine volume is ≥150 mL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Desara® One</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Incision Sling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desara® Blue</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transobturator Sling</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Desara® One Single Incision Sling</intervention_name>
    <description>Single incision sling</description>
    <arm_group_label>Desara® One</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Desara® Blue Transobturator Sling</intervention_name>
    <description>Standard mid-urethral sling</description>
    <arm_group_label>Desara® Blue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female ≥ 18 of age.&#xD;
&#xD;
          2. Subject agrees that she is willing and able to return for all study related procedures&#xD;
             and evaluations.&#xD;
&#xD;
          3. Subject has provided signed informed consent.&#xD;
&#xD;
          4. Subject has stress urinary incontinence (SUI) confirmed by standing cough stress test&#xD;
             (CST) with bladder pre-fill to subjective fullness with 200-300 mL, or with bladder&#xD;
             fullness confirmed via ultrasound.&#xD;
&#xD;
          5. Subject has confirmed stress incontinence greater than urge incontinence per MESA&#xD;
             questionnaire.&#xD;
&#xD;
          6. Subject no longer has childbearing capacity or has a negative pregnancy test and has&#xD;
             decided to cease childbearing. Childbearing capacity to be confirmed by documented&#xD;
             history of:&#xD;
&#xD;
               1. A hysterectomy or&#xD;
&#xD;
               2. Tubal ligation or&#xD;
&#xD;
               3. Is otherwise incapable of pregnancy or has&#xD;
&#xD;
               4. Negative pregnancy test prior to study entry and has decided to cease&#xD;
                  childbearing&#xD;
&#xD;
          7. Subject has been offered and either failed or refused alternative non-invasive SUI&#xD;
             treatment options and has elected to proceed with a surgical intervention.&#xD;
&#xD;
          8. Subject is eligible to undergo laparoscopic/robotic (mesh) or vaginal apical, anterior&#xD;
             or posterior prolapse concomitant surgical repair procedures (non-mesh) before the SUI&#xD;
             implant procedure.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Subject reports baseline pelvic pain ≥ 2 on 10 point Numeric Rating Scale (NRS).&#xD;
&#xD;
          2. Subject has a known neurological disease (with or without signs/symptoms of neurogenic&#xD;
             bladder).&#xD;
&#xD;
          3. Subject has known pre-existing pain syndrome and/or has been evaluated by an&#xD;
             interventional pain management physician.&#xD;
&#xD;
          4. Subject has a history of chronic opioid, or narcotic use for:&#xD;
&#xD;
               1. pain or&#xD;
&#xD;
               2. any other specified reason&#xD;
&#xD;
          5. Subject is on anti-coagulation therapy that cannot be suspended or adjusted for a&#xD;
             minimum of 24-48 hours prior to planned sling implantation surgery.&#xD;
&#xD;
          6. Subject is on chronic (&gt; 3 months) systemic steroid treatment (except for inhalational&#xD;
             use as indicated for pulmonary conditions).&#xD;
&#xD;
          7. Subject has uncontrolled diabetes defined as A1c ≥ 7% or fasting serum glucose &gt;&#xD;
             130mg/dl at screening/baseline.&#xD;
&#xD;
          8. Subject has an active lesion or skin infection of the perineum, urethra, or vagina as&#xD;
             noted per visual pelvic exam.&#xD;
&#xD;
          9. Subject has active UTI defined by a positive urinalysis with ≥ +5 leukocytes and&#xD;
             confirmed with urine culture finding of 10² CFUs (colony forming units).&#xD;
&#xD;
         10. Subject has pattern of recurrent UTIs, defined as ≥ 3 culture-proven UTIs during the&#xD;
             6-month period prior to surgery.&#xD;
&#xD;
         11. Subject has a urethral obstruction or other anatomic defects of the urethra (inclusive&#xD;
             of urethral diverticulum or stricture or bladder neck contracture).&#xD;
&#xD;
         12. The subject has had:&#xD;
&#xD;
               1. any prior surgical stress urinary incontinence treatment or&#xD;
&#xD;
               2. any prior surgery on their urethra or&#xD;
&#xD;
               3. any prior surgery to distal anterior vaginal wall, including fistula repair or&#xD;
                  prior cystocele repair&#xD;
&#xD;
               4. any previous pelvic floor mesh complication&#xD;
&#xD;
         13. Subject has any of the following confounding conditions:&#xD;
&#xD;
               1. bladder stones or tumors&#xD;
&#xD;
               2. pathology that in the opinion of the Investigator would compromise implant&#xD;
                  placement&#xD;
&#xD;
               3. pathology that would limit pelvic blood supply&#xD;
&#xD;
               4. pathology that would require chemotherapy and systemic use of immunosuppressants&#xD;
&#xD;
         14. Subject has abnormal bladder capacity &lt;300 mL.&#xD;
&#xD;
         15. Subject has a post void residual volume ≥ 150 mL on two different measurements.&#xD;
&#xD;
         16. Subject has had previous radiation therapy or brachytherapy to the pelvis.&#xD;
&#xD;
         17. Subject is enrolled in a concurrent clinical trial of any treatment (drug or device)&#xD;
             that could affect continence function, interfere with clinical outcomes, or impact&#xD;
             analysis of this device.&#xD;
&#xD;
         18. Subject has known reaction, sensitivity or allergy to polypropylene.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vicki Gail</last_name>
    <phone>818-483-7602</phone>
    <phone_ext>102</phone_ext>
    <email>vgail@calderamedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra Muhlfeld</last_name>
    <phone>805-558-3024</phone>
    <email>muhlfeld.consulting@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Valley Urogynecology Associates, Inc.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dawn Hill</last_name>
      <phone>602-788-1521</phone>
      <email>dhill@valleyurogyn.com</email>
    </contact>
    <investigator>
      <last_name>Shazia Malik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arizona College of Medicine</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shaman Hashim</last_name>
      <phone>520-626-5935</phone>
      <email>shamamhashim@obgyn.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>llana Addis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology Associates of Norwalk</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teri Jacoby</last_name>
      <phone>208-853-4200</phone>
      <phone_ext>313</phone_ext>
      <email>teri@norwalkurology.com</email>
    </contact>
    <investigator>
      <last_name>Scott Serels, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Health Care Associates P.A. dba Rosemark Women Care Specialists</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candace Coates, BSC</last_name>
      <phone>208-557-2924</phone>
      <email>ccoates@rosemark.net</email>
    </contact>
    <investigator>
      <last_name>Ty Erickson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CMB Research, LLC</name>
      <address>
        <city>Newburgh</city>
        <state>Indiana</state>
        <zip>47630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Douglas</last_name>
      <phone>812-853-3500</phone>
      <email>valerie@drbasinski.com</email>
    </contact>
    <investigator>
      <last_name>Cindy Basinski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaslynn Guerrero, LPN</last_name>
      <phone>502-588-4400</phone>
      <email>Jaslynn.Guerrero@uoflhealth.org</email>
    </contact>
    <investigator>
      <last_name>Sean Francis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mt. Auburn Hospital Division of Urogynecology</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathleen Rogers</last_name>
      <phone>617-354-5452</phone>
      <email>krogers2@mah.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Rosenblatt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Cancer Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen McWhirter</last_name>
      <phone>702-693-6870</phone>
      <email>kmcwhirter@wccenter.com</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Hsieh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cassandra Darley</last_name>
      <phone>505-272-9712</phone>
      <email>CJDarley@salud.unm.edu</email>
    </contact>
    <investigator>
      <last_name>Kate Meriwether, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health Urogynecology</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alanza Ferguson</last_name>
      <phone>704-264-1400</phone>
      <email>aaferguson@novanthealth.org</email>
    </contact>
    <investigator>
      <last_name>William Porter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Lindner Research Center at The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Lamping</last_name>
      <phone>513-585-2166</phone>
      <email>sharon.lamping@thechristhospital.com</email>
    </contact>
    <investigator>
      <last_name>Mickey Karram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Total Women's Health</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorraine Weil</last_name>
      <phone>215-368-1950</phone>
      <email>Lorraine.Weil@axiawh.com</email>
    </contact>
    <investigator>
      <last_name>Donald DeBrakeleer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Pelvic Health</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Gordon</last_name>
      <phone>615-284-4664</phone>
      <email>ashleyg@tncph.org</email>
    </contact>
    <investigator>
      <last_name>Barry Jarnagin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute for Female Pelvic Medicine</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37932</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nancy Yeomans</last_name>
      <phone>865-299-5920</phone>
      <email>nyeomans@ifpm.net</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Dell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stress urinary incontinence</keyword>
  <keyword>female stress urinary incontinence</keyword>
  <keyword>single incision sling</keyword>
  <keyword>transobturator sling</keyword>
  <keyword>Desara® One</keyword>
  <keyword>Desara® Blue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

